OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Sekeres on the Impact of BTK Inhibitors on Approaches to CLL Management

March 4th 2024

Mikkael A. Sekeres, MD, discusses how the emergence of BTK inhibitors have shifted approaches to the management of chronic lymphocytic leukemia.

Dr Lencioni on Unmet Needs in Unresectable HCC

March 4th 2024

Riccardo Lencioni, MD, FSIR, EBIR, discusses unmet needs in unresectable hepatocellular carcinoma.

Dr Obeng-Gyasi on the Impact of Social Determinants of Health on Breast Cancer Outcomes

March 1st 2024

Samilia Obeng-Gyasi, MD, MPH, discusses the impact of social determinants of health on breast cancer care outcomes.

Dr Phillips on the Treatment Landscape for Patients With MCL

March 1st 2024

Tycel Phillips, MD, discusses the landscape of treatment for patients with mantle cell.

Dr Jagsi on the Implications of the IDEA Trial for Radiotherapy Omission in Breast Cancer

March 1st 2024

Reshma Jagsi, MD, Dphil, discusses caveats when interpreting long-term results from the IDEA trial of radiotherapy omission in breast cancer.

Dr Mohindra on Updates in SCLC Management

March 1st 2024

Nisha A. Mohindra, MD, discusses key updates for the management of small cell lung cancer.

Dr Pedersen on Updates in mCRC Management

March 1st 2024

Katrina S. Pedersen, MD, MS, discusses key updates and FDA approvals from 2023 in metastatic colorectal cancer.

Dr Childs on Treatment Updates in mHSPC

March 1st 2024

Dan S. Childs, MD, discusses the evolution of the treatment armamentarium for patients with metastatic hormone-sensitive prostate cancer.

Dr Rini on the Utility of Belzutifan in RCC

March 1st 2024

Brian I. Rini, MD, FASCO, discusses the background that led to the FDA approval of belzutifan for patients with advanced renal cell carcinoma.

Dr Shore on Ongoing Research With Radioligand Therapy in nmCSPC

March 1st 2024

Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.

Dr Meisel on Perceptions of Patient/Provider Communication in Breast Cancer Care

March 1st 2024

Jane L. Meisel, MD, shares information from a study that evaluated patient-reported perceptions of patient-provider communication in breast cancer care.

Dr Wisinski on Treatment Developments in HR+/HER2– Breast Cancer

February 29th 2024

Kari Wisinski, MD, discusses treatment development and the current arsenal for patients with hormone receptor–positive, HER2-negative breast cancer.

Dr Modesitt on Shared Decision-Making When Choosing PARP Inhibitors in Ovarian Cancer

February 29th 2024

Susan C. Modesitt, MD, FACOG, FACS, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr Gopal on the Significance of the EV-302 and CheckMate 901 Trials in mUC

February 29th 2024

Nikhil A. Gopal, MD, discusses how the phase 3 EV-302 and CheckMate 901 trials have advanced the treatment paradigm in metastatic urothelial cancer.

Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

February 29th 2024

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.

Dr Shah on Responses With Pembrolizumab Plus Chemo By PD-1 Status in Esophageal Cancer

February 28th 2024

Manish A. Shah, MD, discusses how pembrolizumab with chemotherapy impacts immune responses in advanced esophageal cancer according to PD-L1 status.

Dr Baldonado on the Evolution of Targeted Therapy in NSCLC

February 28th 2024

Jobelle Baldonado, MD, discusses the evolution of personalized approaches to treatment in non–small cell lung cancer.

Dr DeBernardo on an Ovarian Cancer Patient Case Study

February 28th 2024

Robert DeBernardo, MD, discusses a case study seen in a patient with ovarian cancer.

Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies

February 28th 2024

Alexey Danilov, MD, PhD, discusses unmet needs in hematologic malignancies to be discussed at the Bridging the Gaps in Hematologic Malignancies meeting.

Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL

February 28th 2024

Hayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.